Targeting mitochondria emerges as therapeutic strategy.
Garber
Ken
K
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001713:Biphenyl Compounds / Q000494:pharmacology; D045304:Cytochromes c / Q000187:drug effects; D015507:Drugs, Investigational / Q000494:pharmacology*; D006019:Glycolysis / Q000187:drug effects; D006588:Hexanones / Q000494:pharmacology; D006801:Humans; D008928:Mitochondria / Q000187:drug effects* / Q000378:metabolism; D025261:Mitochondrial Proton-Translocating ATPases / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009596:Nitrophenols; D010879:Piperazines; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors*; D013449:Sulfonamides; D013873:Thionucleotides / Q000494:pharmacology
C501332:ABT-737; D000970:Antineoplastic Agents; D001713:Biphenyl Compounds; D015507:Drugs, Investigational; D006588:Hexanones; D009596:Nitrophenols; D010879:Piperazines; D019253:Proto-Oncogene Proteins c-bcl-2; D013449:Sulfonamides; D013873:Thionucleotides; C014919:4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one; C408162:oblimersen; D045304:Cytochromes c; D025261:Mitochondrial Proton-Translocating ATPases